Rallybio Corp. (RLYB)$15.88
Market Cap: 13.34 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Rallybio Corp. (RLYB).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
0.6x
EV/FCF, 165.3% FCF yield
Quality
-15.5%
ROIC, -3474.7% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 14.5x current ratio
Superinvestors
1
Top: Viking Global Investors (0.0%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Free cash flow margin is negative at -3474.7%.
Annual data: 6 periods
Quarterly data: 23 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for RLYB.
Grade F
2
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| RLYB Target | Rallybio Corp. | $13.3M | -10.0x | 0.6x | -15.5% | N/A | -3474.7% | N/A | N/A | N/A |
| MRKR | Marker Therapeutics Inc. | $13.2M | -1.8x | 0.2x | -72.4% | N/A | N/A | N/A | N/A | N/A |
| CRIS | Curis Inc. | $25.6M | -0.9x | -0.8x | -138.8% | -2.7% | -288.1% | N/A | N/A | N/A |
| PEPG | Pepgen Inc | $47.1M | -0.7x | 0.2x | -60.8% | N/A | N/A | N/A | N/A | N/A |
| GANX | Gain Therapeutics Inc. | $56.4M | -2.9x | -1.9x | -106.3% | N/A | N/A | N/A | N/A | N/A |
| IVVD | Invivyd Inc. | $69.0M | -3.7x | 2.7x | -21.7% | N/A | -109.1% | N/A | N/A | N/A |
| GUTS | Fractyl Health Inc | $79.8M | -0.5x | 0.0x | -1490.3% | N/A | N/A | N/A | N/A | N/A |
| CRBU | Caribou Biosciences Inc. | $79.9M | -1.3x | -0.6x | -121.2% | -2.0% | -1006.8% | N/A | N/A | N/A |
| COYA | Coya Therapeutics Inc | $107.2M | -3.8x | -5.6x | -49.3% | N/A | -135.2% | N/A | N/A | N/A |
Financial Charts
No financial data available for RLYB (annual).
1 superinvestors own RLYB
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 524,347 | $5M | 0.01% | 0.0% |